1 Min Read
Sept 29 (Reuters) - ASPiRA LABs:
* Contract agreement with CareFirst BlueCross BlueShield for their U.S. FDA cleared ovarian cancer risk assessment test, OVA1 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.